NAS
SRPT icon

Nykredit A/S’s Sarepta Therapeutics SRPT Stock Holding History

Nykredit A/S’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.5K Buy
+2,367
New +$44.8K ﹤0.01% 1530

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Nykredit A/S's SRPT Position: Q2 2026 in Review

Nykredit A/S opened a new position in Sarepta Therapeutics (SRPT) in Q2 2026: 2,367 shares worth $42.5K. The stake represents ﹤0.01% of the portfolio and ranks #1530 among its holdings.

234 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Nykredit A/S held 2,367 shares of Sarepta Therapeutics worth $42.5K as of Q2 2026.
  • Sarepta Therapeutics was a new Nykredit A/S position in Q2 2026.
  • Sarepta Therapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1530 holding.
  • 234 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.